Methyl 6-(methoxymethoxy)-1,4-dimethylbenzimidazole-5-carboxylate | 603044-70-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: Methyl 6-(methoxymethoxy)-1,4-dimethylbenzimidazole-5-carboxylate
• CAS: 603044-70-8
• 化学式: C₁₃H₁₆N₂O₄
• 分子量: 264.281
• InChiKey: KQGRMXPDZQKNSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  62.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Methyl 6-(methoxymethoxy)-1,4-dimethylbenzimidazole-5-carboxylate 在 三氟乙酸 作用下， 生成 Methyl 6-hydroxy-1,4-dimethylbenzimidazole-5-carboxylate
  参考文献：
  名称：

  Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III

  摘要：

  Inspired by natural product, LL-Z1640-2, clinical candidate, E6201 ( 22) was discovered in a medicinal chemistry effort through total synthesis. The modification on C14-position to N-alkyl substitution showed to be potent in vitro and orally active in vivo in anti-inflammatory assays. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.087
• 作为产物：
  描述：

  Methyl 2-(methoxymethoxy)-6-methyl-4-(2-trimethylsilylethoxy)benzoate 、 原甲酸三乙酯 、 N-甲基苄胺 在 四丁基氟化铵 、 nitronium tetrafluoborate 作用下， 生成 Methyl 6-(methoxymethoxy)-1,4-dimethylbenzimidazole-5-carboxylate
  参考文献：
  名称：

  Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III

  摘要：

  Inspired by natural product, LL-Z1640-2, clinical candidate, E6201 ( 22) was discovered in a medicinal chemistry effort through total synthesis. The modification on C14-position to N-alkyl substitution showed to be potent in vitro and orally active in vivo in anti-inflammatory assays. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.087

文献信息

• MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS
  申请人：Boivin Roch

  公开号：US20130196987A1

  公开（公告）日：2013-08-01

  The present invention provides compounds, methods for the synthesis thereof and methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis.

  本发明提供了化合物，其合成方法以及在治疗包括炎症或自身免疫性疾病，以及涉及恶性肿瘤或增加血管生成的各种疾病中使用的方法。
• US7799827B2
  申请人：——

  公开号：US7799827B2

  公开（公告）日：2010-09-21
• US7915306B2
  申请人：——

  公开号：US7915306B2

  公开（公告）日：2011-03-29
• Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III
  作者：Yongchun Shen、Roch Boivin、Naoki Yoneda、Hong Du、Shawn Schiller、Tomohiro Matsushima、Masaki Goto、Hiroshi Shirota、Fabian Gusovsky、Charles Lemelin、Yimin Jiang、Zhiyi Zhang、Robert Pelletier、Megumi Ikemori-Kawada、Yoshiyuki Kawakami、Atsushi Inoue、Matthew Schnaderbeck、Yuan Wang

  DOI：10.1016/j.bmcl.2010.03.087

  日期：2010.5

  Inspired by natural product, LL-Z1640-2, clinical candidate, E6201 ( 22) was discovered in a medicinal chemistry effort through total synthesis. The modification on C14-position to N-alkyl substitution showed to be potent in vitro and orally active in vivo in anti-inflammatory assays. (C) 2010 Elsevier Ltd. All rights reserved.